Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.68 |
| ▸ | PPARG | P37231 | 13/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476750 | 1.00 | PPARA (0.68) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6476289 | 0.92 | PPARG (0.74) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6476294 | 0.92 | PPARG (0.74) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6486575 | 0.85 | PPARG (0.65) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6484845 | 0.85 | RAB9A (0.71) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6476836 | 0.85 | PPARA (0.56) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6476834 | 0.85 | PPARA (0.56) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6450149 | 0.84 | PPARG (0.85) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6487594 | 0.83 | PPARG (0.62) | PPARAPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6475313 | 0.83 | PPARG (0.62) | PPARAPPARGNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919362-B2 | Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2005-07-19 | — | — | US | disclosed |
| EP-1252150-B1 | HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | disclosed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | PPARA 845/4885PPARG 414/4885NPC1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.